LRP1

Last updated
LRP1
Protein LRP1 PDB 1cr8.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases LRP1 , A2MR, APOER, APR, CD91, IGFBP3R, LRP, LRP1A, TGFBR5, low density lipoprotein receptor-related protein 1, LDL receptor related protein 1, KPA, IGFBP3R1, IGFBP-3R
External IDs OMIM: 107770 MGI: 96828 HomoloGene: 1744 GeneCards: LRP1
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_002332

NM_008512

RefSeq (protein)

NP_002323

NP_032538

Location (UCSC) Chr 12: 57.13 – 57.21 Mb Chr 10: 127.37 – 127.46 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), apolipoprotein E receptor (APOER) or cluster of differentiation 91 (CD91), is a protein forming a receptor found in the plasma membrane of cells involved in receptor-mediated endocytosis. In humans, the LRP1 protein is encoded by the LRP1 gene. [5] [6] [7] LRP1 is also a key signalling protein and, thus, involved in various biological processes, such as lipoprotein metabolism and cell motility, and diseases, such as neurodegenerative diseases, atherosclerosis, and cancer. [8] [9]

Contents

Structure

The LRP1 gene encodes a 600 kDa precursor protein that is processed by furin in the trans-Golgi complex, resulting in a 515 kDa alpha-chain and an 85 kDa beta-chain associated noncovalently. [8] [10] [11] As a member of the LDLR family, LRP1 contains cysteine-rich complement-type repeats, EGF (gene) repeats, β-propeller domains, a transmembrane domain, and a cytoplasmic domain. [9] The extracellular domain of LRP1 is the alpha-chain, which comprises four ligand-binding domains (numbered I-IV) containing two, eight, ten, and eleven cysteine-rich complement-type repeats, respectively. [8] [9] [10] [11] These repeats bind extracellular matrix proteins, growth factors, proteases, protease inhibitor complexes, and other proteins involved in lipoprotein metabolism. [8] [9] Of the four domains, II and IV bind the majority of the protein's ligands. [11] The EGF repeats and β-propeller domains serve to release ligands in low pH conditions, such as inside endosomes, with the β-propeller postulated to displace the ligand at the ligand binding repeats. [9] The transmembrane domain is the β-chain, which contains a 100-residue cytoplasmic tail. This tail contains two NPxY motifs that are responsible for the protein's function in endocytosis and signal transduction. [8]

Function

LRP1 is a member of the LDLR family and ubiquitously expressed in multiple tissues, though it is most abundant in vascular smooth muscle cells (SMCs), hepatocytes, and neurons. [8] [9] LRP1 plays a key role in intracellular signaling and endocytosis, which implicates it in many cellular and biological processes, including lipid and lipoprotein metabolism, protease degradation, platelet derived growth factor receptor regulation, integrin maturation and recycling, regulation of vascular tone, regulation of blood brain barrier permeability, cell growth, cell migration, inflammation, and apoptosis, as well as diseases such as neurodegenerative diseases, atherosclerosis, and cancer. [7] [8] [9] [10] [11] To elaborate, LRP1 mainly contributes to regulate protein activity by binding target proteins as a co-receptor, in conjunction with integral membrane proteins or adaptor proteins like uPA, to the lysosome for degradation. [9] [10] [11] In lipoprotein metabolism, the interaction between LRP1 and APOE stimulates a signaling pathway that leads to elevated intracellular cAMP levels, increased protein kinase A activity, inhibited SMC migration, and ultimately, protection against vascular disease. [9] While membrane-bound LRP1 performs endocytic clearance of proteases and inhibitors, proteolytic cleavage of its ectodomain allows the free LRP1 to compete with the membrane-bound form and prevent their clearance. [8] Several sheddases have been implicated in the proteolytic cleavage of LRP1 such as ADAM10, [12] ADAM12, [13] ADAM17 [14] and MT1-MMP. [13] LRP1 is also continuously endocytosed from the membrane and recycled back to the cell surface. [9] Though the role of LRP1 in apoptosis is unclear, it is required for tPA to bind LRP1 in order to trigger the ERK1/2 signal cascade and promote cell survival. [15]

Clinical significance

Alzheimer's disease

Neurons require cholesterol to function. Cholesterol is imported into the neuron by apolipoprotein E (apoE) via LRP1 receptors on the cell surface. It has been theorized that a causal factor in Alzheimer's is the decrease of LRP1 mediated by the metabolism of the amyloid precursor protein, leading to decreased neuronal cholesterol and increased amyloid beta. [16]

LRP1 is also implicated in the effective clearance of Aβ from the brain to the periphery across the blood-brain barrier. [17] [18] LRP1 mediates pathways that interact with astrocytes and pericytes, which are associated with the blood-brain barrier. In support of this, LRP1 expression is reduced in endothelial cells as a result of normal aging and Alzheimer's disease in humans and animal models of the disease. [19] [20] This clearance mechanism is modulated by the apoE isoforms, with the presence of the apoE4 isoform resulting in reduced transcytosis of Aβ in in vitro models of the blood-brain barrier. [21] The reduced clearance appears to be, at least in part, as a result of an increase in the ectodomain shedding of LRP1 by sheddases, resulting in the formation of soluble LRP1 which is no longer able to transcytose the Aβ peptides. [22]

In addition, over-accumulation of copper in the brain is associated with reduced LRP1 mediated clearance of amyloid beta across the blood brain barrier. This defective clearance may contribute to the buildup of neurotoxic amyloid-beta that is thought to contribute to Alzheimer's disease. [23]

Cardiovascular disease

Studies have elucidated different roles for LRP1 in cellular processes relevant for cardiovascular disease. Atherosclerosis is the primary cause of cardiovascular disease such as stroke and heart attacks. In the liver LRP1 is important for the removal of atherogenic lipoproteins (Chylomicron remnants, VLDL) and other proatherogenic ligands from the circulation. [24] [25] LRP1 has a cholesterol-independent role in atherosclerosis by modulating the activity and cellular localization of the PDGFR-β in vascular smooth muscle cells. [26] [27] Finally, LRP1 in macrophages has an effect on atherosclerosis through the modulation of the extracellular matrix and inflammatory responses. [28] [29]

Cancer

LRP1 is involved in tumorigenesis, and is proposed to be a tumor suppressor. Notably, LRP1 functions in clearing proteases such as plasmin, urokinase-type plasminogen activator, and metalloproteinases, which contributes to prevention of cancer invasion, while its absence is linked to increased cancer invasion. However, the exact mechanisms require further study, as other studies have shown that LRP1 may also promote cancer invasion. One possible mechanism for the inhibitory function of LRP1 in cancer involves the LRP1-dependent endocytosis of 2′-hydroxycinnamaldehyde (HCA), resulting in decreased pepsin levels and, consequently, tumor progression. [9] Alternatively, LRP1 may regulate focal adhesion disassembly of cancer cells through the ERK and JNK pathways to aid invasion. [8] Moreover, LRP1 interacts with PAI-1 to recruit mast cells (MCs) and induce their degranulation, resulting in the release of MC mediators, activation of an inflammatory response, and development of glioma. [10]

Interactions

LRP1 has been shown to interact with:

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. [§ 1]

[[File:
StatinPathway WP430.png go to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to article
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
StatinPathway WP430.png go to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to article
|alt=Statin Pathway edit]]
Statin Pathway edit
  1. The interactive pathway map can be edited at WikiPathways: "Statin_Pathway_WP430".

See also

Related Research Articles

High-density lipoprotein (HDL) is one of the five major groups of lipoproteins. Lipoproteins are complex particles composed of multiple proteins which transport all fat molecules (lipids) around the body within the water outside cells. They are typically composed of 80–100 proteins per particle. HDL particles enlarge while circulating in the blood, aggregating more fat molecules and transporting up to hundreds of fat molecules per particle.

<span class="mw-page-title-main">Low-density lipoprotein</span> One of the five major groups of lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water. These groups, from least dense to most dense, are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL delivers fat molecules to cells. LDL is involved in atherosclerosis, a process in which it is oxidized within the walls of arteries.

<span class="mw-page-title-main">Lipoprotein</span> Biochemical assembly whose purpose is to transport hydrophobic lipid molecules

A lipoprotein is a biochemical assembly whose primary function is to transport hydrophobic lipid molecules in water, as in blood plasma or other extracellular fluids. They consist of a triglyceride and cholesterol center, surrounded by a phospholipid outer shell, with the hydrophilic portions oriented outward toward the surrounding water and lipophilic portions oriented inward toward the lipid center. A special kind of protein, called apolipoprotein, is embedded in the outer shell, both stabilising the complex and giving it a functional identity that determines its role.

<span class="mw-page-title-main">Lipoprotein lipase</span> Mammalian protein found in Homo sapiens

Lipoprotein lipase (LPL) (EC 3.1.1.34, systematic name triacylglycerol acylhydrolase (lipoprotein-dependent)) is a member of the lipase gene family, which includes pancreatic lipase, hepatic lipase, and endothelial lipase. It is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins, such as those found in chylomicrons and very low-density lipoproteins (VLDL), into two free fatty acids and one monoacylglycerol molecule:

Hyperlipidemia is abnormally elevated levels of any or all lipids or lipoproteins in the blood. The term hyperlipidemia refers to the laboratory finding itself and is also used as an umbrella term covering any of various acquired or genetic disorders that result in that finding. Hyperlipidemia represents a subset of dyslipidemia and a superset of hypercholesterolemia. Hyperlipidemia is usually chronic and requires ongoing medication to control blood lipid levels.

Scavenger receptors are a large and diverse superfamily of cell surface receptors. Its properties were first recorded in 1970 by Drs. Brown and Goldstein, with the defining property being the ability to bind and remove modified low density lipoproteins (LDL). Today scavenger receptors are known to be involved in a wide range of processes, such as: homeostasis, apoptosis, inflammatory diseases and pathogen clearance. Scavenger receptors are mainly found on myeloid cells and other cells that bind to numerous ligands, primarily endogenous and modified host-molecules together with pathogen-associated molecular patterns(PAMPs), and remove them. The Kupffer cells in the liver are particularly rich in scavenger receptors, includes SR-A I, SR-A II, and MARCO.

<span class="mw-page-title-main">LDL receptor</span> Mammalian protein found in Homo sapiens

The low-density lipoprotein receptor (LDL-R) is a mosaic protein of 839 amino acids that mediates the endocytosis of cholesterol-rich low-density lipoprotein (LDL). It is a cell-surface receptor that recognizes apolipoprotein B100 (ApoB100), which is embedded in the outer phospholipid layer of very low-density lipoprotein (VLDL), their remnants—i.e. intermediate-density lipoprotein (IDL), and LDL particles. The receptor also recognizes apolipoprotein E (ApoE) which is found in chylomicron remnants and IDL. In humans, the LDL receptor protein is encoded by the LDLR gene on chromosome 19. It belongs to the low density lipoprotein receptor gene family. It is most significantly expressed in bronchial epithelial cells and adrenal gland and cortex tissue.

<span class="mw-page-title-main">Low-density lipoprotein receptor gene family</span>

The low-density lipoprotein receptor gene family codes for a class of structurally related cell surface receptors that fulfill diverse biological functions in different organs, tissues, and cell types. The role that is most commonly associated with this evolutionarily ancient family is cholesterol homeostasis. In humans, excess cholesterol in the blood is captured by low-density lipoprotein (LDL) and removed by the liver via endocytosis of the LDL receptor. Recent evidence indicates that the members of the LDL receptor gene family are active in the cell signalling pathways between specialized cells in many, if not all, multicellular organisms.

<span class="mw-page-title-main">VLDL receptor</span> Protein-coding gene in the species Homo sapiens

The very-low-density-lipoprotein receptor (VLDLR) is a transmembrane lipoprotein receptor of the low-density-lipoprotein (LDL) receptor family. VLDLR shows considerable homology with the members of this lineage. Discovered in 1992 by T. Yamamoto, VLDLR is widely distributed throughout the tissues of the body, including the heart, skeletal muscle, adipose tissue, and the brain, but is absent from the liver. This receptor has an important role in cholesterol uptake, metabolism of apolipoprotein E-containing triacylglycerol-rich lipoproteins, and neuronal migration in the developing brain. In humans, VLDLR is encoded by the VLDLR gene. Mutations of this gene may lead to a variety of symptoms and diseases, which include type I lissencephaly, cerebellar hypoplasia, and atherosclerosis.

<span class="mw-page-title-main">Foam cell</span> Fat-laden M2 macrophages seen in atherosclerosis

Foam cells, also called lipid-laden macrophages, are a type of cell that contain cholesterol. These can form a plaque that can lead to atherosclerosis and trigger heart attacks and stroke.

<span class="mw-page-title-main">LDL-receptor-related protein-associated protein</span> Protein-coding gene in the species Homo sapiens

Low density lipoprotein receptor-related protein-associated protein 1 also known as LRPAP1 or RAP is a chaperone protein which in humans is encoded by the LRPAP1 gene.

<span class="mw-page-title-main">Low-density lipoprotein receptor-related protein 8</span> Cell surface receptor, part of the low-density lipoprotein receptor family

Low-density lipoprotein receptor-related protein 8 (LRP8), also known as apolipoprotein E receptor 2 (ApoER2), is a protein that in humans is encoded by the LRP8 gene. ApoER2 is a cell surface receptor that is part of the low-density lipoprotein receptor family. These receptors function in signal transduction and endocytosis of specific ligands. Through interactions with one of its ligands, reelin, ApoER2 plays an important role in embryonic neuronal migration and postnatal long-term potentiation. Another LDL family receptor, VLDLR, also interacts with reelin, and together these two receptors influence brain development and function. Decreased expression of ApoER2 is associated with certain neurological diseases.

The epididymal secretory protein E1, also known as NPC2( Niemann-Pick intracellular cholesterol transporter 2), is one of two main lysosomal transport proteins that assist in the regulation of cellular cholesterol by exportation of LDL-derived cholesterol from lysosomes. Lysosomes have digestive enzymes that allow it to break down LDL particles to LDL-derived cholesterol once the LDL particle is engulfed into the cell via receptor mediated endocytosis.

Soluble low-density lipoprotein receptor-related protein is a biological substance naturally produced by the human body. This protein has been found to bind to and neutralize anywhere from 70 to 90 percent of the amyloid-beta peptide that also naturally circulates in healthy human or mouse plasma. Impairment of this function is strongly associated with, and may soon be shown definitively to be the principal cause of, Alzheimer's disease.

<span class="mw-page-title-main">OLR1</span> Protein-coding gene in the species Homo sapiens

Oxidized low-density lipoprotein receptor 1 also known as lectin-type oxidized LDL receptor 1 (LOX-1) is a protein that in humans is encoded by the OLR1 gene.

<span class="mw-page-title-main">LRP2</span> Mammalian protein found in Homo sapiens

Low density lipoprotein receptor-related protein 2 also known as LRP-2 or megalin is a protein which in humans is encoded by the LRP2 gene.

<span class="mw-page-title-main">LRP5</span> Protein-coding gene in the species Homo sapiens

Low-density lipoprotein receptor-related protein 5 is a protein that in humans is encoded by the LRP5 gene. LRP5 is a key component of the LRP5/LRP6/Frizzled co-receptor group that is involved in canonical Wnt pathway. Mutations in LRP5 can lead to considerable changes in bone mass. A loss-of-function mutation causes osteoporosis pseudoglioma syndrome with a decrease in bone mass, while a gain-of-function mutation causes drastic increases in bone mass.

<span class="mw-page-title-main">LRP6</span> Protein-coding gene in the species Homo sapiens

Low-density lipoprotein receptor-related protein 6 is a protein that in humans is encoded by the LRP6 gene. LRP6 is a key component of the LRP5/LRP6/Frizzled co-receptor group that is involved in canonical Wnt pathway.

<span class="mw-page-title-main">Low-density lipoprotein receptor adapter protein 1</span> Protein-coding gene in the species Homo sapiens

Low-density lipoprotein receptor adapter protein 1 is a protein that in humans is encoded by the LDLRAP1 gene.

<span class="mw-page-title-main">LRP1B</span> Protein-coding gene in the species Homo sapiens

Low-density lipoprotein receptor-related protein 1B is a protein that in humans is encoded by the LRP1B gene.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000123384 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000040249 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK (Dec 1988). "Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor". The EMBO Journal. 7 (13): 4119–27. doi:10.1002/j.1460-2075.1988.tb03306.x. PMC   455121 . PMID   3266596.
  6. Myklebost O, Arheden K, Rogne S, Geurts van Kessel A, Mandahl N, Herz J, Stanley K, Heim S, Mitelman F (Jul 1989). "The gene for the human putative apoE receptor is on chromosome 12 in the segment q13-14". Genomics. 5 (1): 65–9. doi:10.1016/0888-7543(89)90087-6. PMID   2548950.
  7. 1 2 "Entrez Gene: LRP1 low density lipoprotein receptor-related protein 1".
  8. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Etique N, Verzeaux L, Dedieu S, Emonard H (2013). "LRP-1: a checkpoint for the extracellular matrix proteolysis". BioMed Research International. 2013: 152163. doi: 10.1155/2013/152163 . PMC   3723059 . PMID   23936774.
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Lillis AP, Mikhailenko I, Strickland DK (Aug 2005). "Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability". Journal of Thrombosis and Haemostasis. 3 (8): 1884–93. doi: 10.1111/j.1538-7836.2005.01371.x . PMID   16102056. S2CID   20991690.
  10. 1 2 3 4 5 6 Roy A, Coum A, Marinescu VD, Põlajeva J, Smits A, Nelander S, Uhrbom L, Westermark B, Forsberg-Nilsson K, Pontén F, Tchougounova E (Jun 2015). "Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells". Oncotarget. 6 (27): 23647–61. doi:10.18632/oncotarget.4640. PMC   4695142 . PMID   26164207.
  11. 1 2 3 4 5 Kang HS, Kim J, Lee HJ, Kwon BM, Lee DK, Hong SH (Aug 2014). "LRP1-dependent pepsin clearance induced by 2'-hydroxycinnamaldehyde attenuates breast cancer cell invasion". The International Journal of Biochemistry & Cell Biology. 53: 15–23. doi:10.1016/j.biocel.2014.04.021. PMID   24796846.
  12. Shackleton, B.; Crawford, F.; Bachmeier, C. (2016-08-08). "Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding". Fluids and Barriers of the CNS. 13 (1): 14. doi: 10.1186/s12987-016-0038-x . ISSN   2045-8118. PMC   4977753 . PMID   27503326.
  13. 1 2 Selvais, Charlotte; D'Auria, Ludovic; Tyteca, Donatienne; Perrot, Gwenn; Lemoine, Pascale; Troeberg, Linda; Dedieu, Stéphane; Noël, Agnès; Nagase, Hideaki (2017-03-31). "Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function". The FASEB Journal. 25 (8): 2770–2781. doi:10.1096/fj.10-169508. ISSN   0892-6638. PMC   3470721 . PMID   21518850.
  14. Liu, Qiang; Zhang, Juan; Tran, Hien; Verbeek, Marcel M.; Reiss, Karina; Estus, Steven; Bu, Guojun (2009-04-16). "LRP1 shedding in human brain: roles of ADAM10 and ADAM17". Molecular Neurodegeneration. 4: 17. doi: 10.1186/1750-1326-4-17 . ISSN   1750-1326. PMC   2672942 . PMID   19371428.
  15. Hu K, Lin L, Tan X, Yang J, Bu G, Mars WM, Liu Y (Mar 2008). "tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis". Journal of the American Society of Nephrology. 19 (3): 503–14. doi:10.1681/ASN.2007030300. PMC   2391054 . PMID   18199803.
  16. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G (Oct 2007). "Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1". Neuron. 56 (1): 66–78. doi:10.1016/j.neuron.2007.08.008. PMC   2045076 . PMID   17920016.
  17. Deane, R; Bell, RD; Sagare, A; Zlokovic, BV (2017-03-31). "Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease". CNS & Neurological Disorders Drug Targets. 8 (1): 16–30. doi:10.2174/187152709787601867. ISSN   1871-5273. PMC   2872930 . PMID   19275634.
  18. Storck, Steffen E.; Meister, Sabrina; Nahrath, Julius; Meißner, Julius N.; Schubert, Nils; Spiezio, Alessandro Di; Baches, Sandra; Vandenbroucke, Roosmarijn E.; Bouter, Yvonne (2016-01-04). "Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier". The Journal of Clinical Investigation. 126 (1): 123–136. doi:10.1172/JCI81108. ISSN   0021-9738. PMC   4701557 . PMID   26619118.
  19. Kang, D. E.; Pietrzik, C. U.; Baum, L.; Chevallier, N.; Merriam, D. E.; Kounnas, M. Z.; Wagner, S. L.; Troncoso, J. C.; Kawas, C. H. (2000-11-01). "Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway". The Journal of Clinical Investigation. 106 (9): 1159–1166. doi:10.1172/JCI11013. ISSN   0021-9738. PMC   301422 . PMID   11067868.
  20. Shibata, M.; Yamada, S.; Kumar, S. R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D. M.; Miller, C. A.; Strickland, D. K. (2000-12-01). "Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier". The Journal of Clinical Investigation. 106 (12): 1489–1499. doi:10.1172/JCI10498. ISSN   0021-9738. PMC   387254 . PMID   11120756.
  21. Bachmeier, Corbin; Paris, Daniel; Beaulieu-Abdelahad, David; Mouzon, Benoit; Mullan, Michael; Crawford, Fiona (2013-01-01). "A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier". Neuro-Degenerative Diseases. 11 (1): 13–21. doi:10.1159/000337231. ISSN   1660-2862. PMID   22572854. S2CID   30189180.
  22. Bachmeier, Corbin; Shackleton, Ben; Ojo, Joseph; Paris, Daniel; Mullan, Michael; Crawford, Fiona (2017-03-31). "Apolipoprotein E isoform-specific effects on lipoprotein receptor processing". Neuromolecular Medicine. 16 (4): 686–696. doi:10.1007/s12017-014-8318-6. ISSN   1535-1084. PMC   4280344 . PMID   25015123.
  23. Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, Deane RJ, Zhong E, Parisi M, Ciszewski J, Kasper RT, Deane R (Sep 2013). "Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance". Proceedings of the National Academy of Sciences of the United States of America. 110 (36): 14771–6. Bibcode:2013PNAS..11014771S. doi: 10.1073/pnas.1302212110 . PMC   3767519 . PMID   23959870.
  24. Gordts PL, Reekmans S, Lauwers A, Van Dongen A, Verbeek L, Roebroek AJ (Sep 2009). "Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis". Arteriosclerosis, Thrombosis, and Vascular Biology. 29 (9): 1258–64. doi: 10.1161/ATVBAHA.109.192211 . PMID   19667105.
  25. Rohlmann A, Gotthardt M, Hammer RE, Herz J (Feb 1998). "Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants". The Journal of Clinical Investigation. 101 (3): 689–95. doi:10.1172/JCI1240. PMC   508614 . PMID   9449704.
  26. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J (Apr 2003). "LRP: role in vascular wall integrity and protection from atherosclerosis". Science. 300 (5617): 329–32. Bibcode:2003Sci...300..329B. doi:10.1126/science.1082095. PMID   12690199. S2CID   2070128.
  27. Boucher P, Li WP, Matz RL, Takayama Y, Auwerx J, Anderson RG, Herz J (2007). "LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome". PLOS ONE. 2 (5): e448. Bibcode:2007PLoSO...2..448B. doi: 10.1371/journal.pone.0000448 . PMC   1864997 . PMID   17505534. Open Access logo PLoS transparent.svg
  28. Yancey PG, Ding Y, Fan D, Blakemore JL, Zhang Y, Ding L, Zhang J, Linton MF, Fazio S (Jul 2011). "Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent". Circulation. 124 (4): 454–64. doi:10.1161/CIRCULATIONAHA.111.032268. PMC   3144781 . PMID   21730304.
  29. Overton CD, Yancey PG, Major AS, Linton MF, Fazio S (Mar 2007). "Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse". Circulation Research. 100 (5): 670–7. doi: 10.1161/01.RES.0000260204.40510.aa . PMID   17303763.
  30. Trommsdorff M, Borg JP, Margolis B, Herz J (Dec 1998). "Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein". The Journal of Biological Chemistry. 273 (50): 33556–60. doi: 10.1074/jbc.273.50.33556 . PMID   9837937.
  31. Poswa M (Mar 1977). "[Team growth by acquiring an apprentice]". Quintessenz Journal. 7 (3): 21–3. PMID   277965.
  32. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS (Aug 1989). "Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins". Proceedings of the National Academy of Sciences of the United States of America. 86 (15): 5810–4. Bibcode:1989PNAS...86.5810K. doi: 10.1073/pnas.86.15.5810 . PMC   297720 . PMID   2762297.
  33. Orr AW, Pedraza CE, Pallero MA, Elzie CA, Goicoechea S, Strickland DK, Murphy-Ullrich JE (Jun 2003). "Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly". The Journal of Cell Biology. 161 (6): 1179–89. doi:10.1083/jcb.200302069. PMC   2172996 . PMID   12821648.
  34. 1 2 3 4 5 6 7 Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J (Aug 2000). "Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction". The Journal of Biological Chemistry. 275 (33): 25616–24. doi: 10.1074/jbc.M000955200 . PMID   10827173.
  35. Basu S, Binder RJ, Ramalingam T, Srivastava PK (Mar 2001). "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin". Immunity. 14 (3): 303–13. doi: 10.1016/s1074-7613(01)00111-x . PMID   11290339.
  36. Williams SE, Inoue I, Tran H, Fry GL, Pladet MW, Iverius PH, Lalouel JM, Chappell DA, Strickland DK (Mar 1994). "The carboxyl-terminal domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and mediates binding of normal very low density lipoproteins to LRP". The Journal of Biological Chemistry. 269 (12): 8653–8. doi: 10.1016/S0021-9258(17)37017-5 . PMID   7510694.
  37. Nykjaer A, Nielsen M, Lookene A, Meyer N, Røigaard H, Etzerodt M, Beisiegel U, Olivecrona G, Gliemann J (Dec 1994). "A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake of lipoprotein in cells". The Journal of Biological Chemistry. 269 (50): 31747–55. doi: 10.1016/S0021-9258(18)31759-9 . PMID   7989348.
  38. Chappell DA, Fry GL, Waknitz MA, Iverius PH, Williams SE, Strickland DK (Dec 1992). "The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase". The Journal of Biological Chemistry. 267 (36): 25764–7. doi: 10.1016/S0021-9258(18)35675-8 . PMID   1281473.
  39. Barnes H, Ackermann EJ, van der Geer P (Jun 2003). "v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1". Oncogene. 22 (23): 3589–97. doi: 10.1038/sj.onc.1206504 . PMID   12789267.
  40. Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK (May 2002). "Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF". The Journal of Biological Chemistry. 277 (18): 15499–506. doi: 10.1074/jbc.M200427200 . PMID   11854294.
  41. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS, Liau G (Mar 2004). "Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans". Journal of Cellular Biochemistry. 91 (4): 766–76. doi:10.1002/jcb.10781. PMID   14991768. S2CID   12198474.
  42. Mikhailenko I, Krylov D, Argraves KM, Roberts DD, Liau G, Strickland DK (Mar 1997). "Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein". The Journal of Biological Chemistry. 272 (10): 6784–91. doi: 10.1074/jbc.272.10.6784 . PMID   9045712.
  43. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS (Jun 1995). "Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1". The Journal of Cell Biology. 129 (5): 1403–10. doi:10.1083/jcb.129.5.1403. PMC   2120467 . PMID   7775583.
  44. Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G (Jan 2000). "Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation". The Journal of Neuroscience. 20 (2): 542–9. doi:10.1523/JNEUROSCI.20-02-00542.2000. PMC   6772406 . PMID   10632583.
  45. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J (Aug 1992). "Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor". Proceedings of the National Academy of Sciences of the United States of America. 89 (16): 7422–6. Bibcode:1992PNAS...89.7422O. doi: 10.1073/pnas.89.16.7422 . PMC   49722 . PMID   1502153.
  46. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG (May 2001). "Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity". Molecular Biology of the Cell. 12 (5): 1467–79. doi:10.1091/mbc.12.5.1467. PMC   34598 . PMID   11359936.

Further reading